Austin Bigley

Austin Bigley

Company: Indapta Therapeutics

Job title: Vice President & Director of Research & Development

Seminars:

Closing Panel: The Future of Innate Immune Checkpoints & Activation 2:30 pm

Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment Discussing novel checkpoint inhibitors Analysing the various immunotherapy approaches discussed & beyond Updates on clinical trials for immunotherapies In vitro models and discovery technologies for innate cell-based therapies New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq,…Read more

day: Innate Immune Checkpoints & Activation Pre-Focus Day

Utilizing the Superior Antibody-Dependent Cellular Cytotoxicity, Effector Functions, & Improved Persistence of g-NK Cells When Compared to Conventional NK cells 10:00 am

Discussing the enhanced in vivo efficacy and persistence of g-NK cells and the ability of g-NK cells to induce regression of established tumors leading to durable elimination of tumor burden Elucidating the unique feature of g-NK cells which enable the development of an off-the-shelf cancer immunotherapy combined with therapeutic IgG antibodies Combining g-NK cells with…Read more

day: Innate Immune Checkpoints & Activation Pre-Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.